Concepedia

Author

Claes Karlsson

Karolinska University HospitalORCID

Also Known As

C Karlsson, C. Karlsson, Claes Karlsson, Karlsson, C.,  Claes Karlsson 

37

Publications

1.4K

Citations

15

H-Index

19

Concepts

All Affiliations

Karolinska University HospitalKarolinska InstitutetJanssen (United States)Sunderby sjukhusUppsala University Hospital
CK

About

Claes Karlsson is an author at Karolinska University Hospital specializing in immunology, medicine, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

757

2

Immunology

7

7

757

3

Health Sciences

3

3

163

4

Pathology

2

2

522

5

Molecular Medicine

1

1

114

Claes Karlsson

×

12

Publications

1.1K

Citations

11

H-Index

YearCitations

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan,

The Lancet Oncology

2015

408

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid,

Nature Cancer

2022

120

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

Jeanette Lundin, Anna Porwit‐MacDonald, Eva Rossmann,

Leukemia

2004

118

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Graeme Fraser, Paula Cramer, Rodrigo Santucci Alves da Silva,

Leukemia

2018

116

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

Maria Winqvist, Anna Asklid, Per Andersson,

Haematologica

2016

114

Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody)

Claes Karlsson, Lotta Hansson, Fredrik Celsing,

Leukemia

2007

59

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

Sandra Eketorp Sylvan, Anna Asklid, Hemming Johansson,

Haematologica

2018

35

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia

Claes Karlsson, Jeanette Lundin, Eva Kimby,

British Journal of Haematology

2008

31

Reconstitution of the T‐cell repertoire following treatment with alemtuzumab (anti‐CD52 monoclonal antibody) in patients with B‐cell chronic lymphocytic leukaemia

Mohammad Reza Rezvany, Mahmood Jeddi‐Tehrani, Claes Karlsson,

British Journal of Haematology

2006

23

Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.

Jeanette Lundin, Claes Karlsson, Fredrik Celsing

Medical Oncology

2006

14

Page 1